Ueno, M., Li, C. P., Ikeda, M., Ishii, H., Mizuno, N., Yamaguchi, T., . . . Furuse, J. (2017). A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol.
Chicago Stili AlıntıUeno, Makoto, et al. "A Randomized Phase II Study of Gemcitabine Plus Z-360, a CCK2 Receptor-selective Antagonist, in Patients With Metastatic Pancreatic Cancer As Compared With Gemcitabine Plus Placebo." Cancer Chemother Pharmacol 2017.
MLA AlıntıUeno, Makoto, et al. "A Randomized Phase II Study of Gemcitabine Plus Z-360, a CCK2 Receptor-selective Antagonist, in Patients With Metastatic Pancreatic Cancer As Compared With Gemcitabine Plus Placebo." Cancer Chemother Pharmacol 2017.